Wastewater reuse has emerged as a trusty method to combat water scarcity, but contaminants are still being found, say Israeli researchers.

CytoReason said it plans to present insights on the top drug targets to provide new therapeutic options for IBD patients.

As part of the agreement, Dvir's lab and Bayer will aim to test new cardiology medication for toxicity and efficacy.

Founded in 2016, CytoReason already has partnerships with top global pharmaceutical companies.

The company's propriety platform combines scientific and experimental data for immune system simulations applicable to cancer immunotherapy, and autoimmune, neurodegenerative and infectious disease research.

Researchers at the Hebrew University of Jerusalem have developed a new platform for drug creation and delivery, which they will present at the 3D Printing and Beyond conference.